[1] TREVISANI FRANCO, GARUTI FRANCESCA, NERI ANDREA, et al.Alpha-fetoprotein for Diagnosis, Prognosis, and Transplant Selection[J].Semin Liver Dis, 2019, 39(2): 163-177. [2] GALLE PETER R, FOERSTER FRIEDRICH, KUDO MASATOSHI, et al.Biology and significance of alpha-fetoprotein in hepatocellular Carcinoma[J].Liver Int, 2019, 39(12): 2214-2229. [3] WORLAND T, HARRISON B, DELMENICO L, DOWLING D.Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis[J]. J Gastrointest Cancer, 2018, 49(4): 476-480. [4] TSUCHIYA N, SAWADA Y, ENDO I, et al.Biomarkers for the early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2015,21(37): 10573-10583. [5] WANG X, ZHANG Y, YANG N, et al.Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis[J]. Biomed Res Int, 2020,17(2020): 5087643. [6] QI F, ZHOU A, YAN L, et al.The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma[J].J Clin Lab Anal, 2019, 34(5): e23158. [7] YEN CW, KUO YH, WANG JH, et al.Did AFP-L3 save ultrasonography in community screening?[J]. Kaohsiung J Med Sci, 2018, 34(10): 583-587. [8] STREICHER JM.The Role of Heat Shock Proteins in Regulating Receptor Signal Transduction[J]. Mol Pharmacol, 2019, 95(5): 468-474. [9] SUN Y, ZANG Z, XU X, et al.Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry[J]. Int J Mol Sci, 2010, 11(4): 1423-1433. [10] FU Y, XU X, HUANG D, et al.Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: an official, large-scale, and multicenter clinical trial[J]. EBioMedicine, 2017, 24: 56-63. [11] LU F.Serological diagnosis of hepatocelllulat carcinoma: challenge and opportunities[J]. J Clin Hepatol , 2017, 33(7): 1262-1265. [12] N ZEKRI AR, El KASSAS M, SALAM ESE. The possible role of Dickkopf-1, Golgi protein-73 and Midkine as predictors of hepatocarcinogenesis: a review and an Egyptian study[J]. Sci Rep, 2020, 10(1): 5156. [13] WONG RJ, AHMED A, GISH RG.Elevated alpha-fetoprotein: differential diagnosis-hepatocellular carcinoma and other disorders[J]. Clin Liver Dis, 2015, 19(2): 309-323. [14] DE J, SHEN Y, QIN J, et al.A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma[J]. Medicine (Baltimore), 2016, 95(17): e3448. [15] TSUKAMOTO M, NITTA H, IMIA K, et al.Clinical significance of half-lives of tumor markers α-fetoprotein and des-γ-carboxy prothrombin after hepatectomy for hepatocellular carcinoma[J]. Hepatol Res, 2018 ,48(3): E183-E193. [16] SI YQ, WANG XQ, FAN G, et al. Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation[J]. Infect Agent Cancer, 2020, 23; 15(1): 70. [17] LIN ZZ, HSU C, JENG YM, et al.Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma[J]. Liver Int, 2019, 39(9): 1682-1691. [18] TSUKAMOTO M, NITTA H, IMAI K, et al. Clinical significance of half-lives of tumor markers α- fetoprotein and des-γ-carboxy prothrombin after hepatectomy for hepatocellular carcinoma[J]. Hepatol Res, 2018, 48(3): E183‐E193. [19] HARUYAMA Y, KATAOKA H.Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(1): 275-83. [20] HAN N, WANG W, LU D,et al.A novel, rapid, and sensitive homogeneous sandwich detection method of Glypican-3 as a serum marker for hepatocellular carcinoma[J]. Chem Commun (Camb), 2017 ,53(90): 12209-12212. [21] VONGSUVANH R, VAN DER POORTEN D, ISELIT,et al. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma[J]. PLoSOne, 2016, 24; 11(5): e0155800. [22] LU Q, LI J, CAO H, et al. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis[J]. Biosci Rep, 2020, 27; 40(3): 2019-2424. [23] ZHU WW, GUO JJ, GUO L, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma[J]. Clin Cancer Res, 2013, 19(14): 3944‐3954. [24] HUANG H, WENG H, SUN W, et al.Author Correction: Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation[J]. Nat Cell Biol, 2018, 20(9): 1098. [25] LIU GM, ZENG HD, ZHANG CY, et al.Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma[J]. Dig Dis Sci, 2021, 66(4): 1110-1126. [26] LI J, WANG J, LEI L, et al.The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies[J]. Eur Radiol, 2019, 29(12): 6519-6528. [27] YAN L, XU F, DAI C. Overexpression of COL24A1 in Hepatocellular Carcinoma Predicts Poor Prognosis: A Study Based on Multiple Databases, Clinical Samples and Cell Lines[J]. Onco Targets Ther, 2020, 2; 13: 2819-2832. [28] TAN C, CAO J, CHEN L, et al.Noncoding RNAs Serve as Diagnosis and Prognosis Biomarkers for Hepatocellular Carcinoma[J]. Clin Chem, 2019, 65(7): 905-915. [29] LEE YR, KIM G, TAKWY, et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma[J]. Int J Cancer, 2019, 144(6): 1444-1452. [30] TAN C, CAO J, CHEN L, et al.Noncoding RNAs Serve as Diagnosis and Prognosis Biomarkers for Hepatocellular Carcinoma[J]. Clin Chem, 2019, 65(7): 905-915. [31] JUN L, YANG G, ZHISU L.The utility of serum exosomal microRNAs in hepatocellular carcinoma[J]. Biomed Pharmacother, 2019, 111: 1221-1227. [32] HOAC B, NELEA V, JIANG W, et al.Mineralization-inhibiting effects of transglutaminase-crosslinked polymeric osteopontin[J]. Bone, 2017, 101: 37-48. [33] LI J, CHEN X, DAI M, et a. Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2017,41(5): 543-553. [34] GAO X, SHENG Y, YANG J, et al.Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1): 179. [35] HUAMAN J, NAIDOO M, ZANG X, et al.Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells[J]. Cells, 2019, 8(6): 618. [36] GUO W, SUN YF, SHEN MN, et al.Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma[J]. Clin Cancer Res, 2018, 24(9): 2203-2213. [37] NG CKY, DI COSTANZO GG, TOSTI N, et al.Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study[J]. Ann Oncol, 2018, 29(5): 1286-1291. [38] HUANG A, ZHANG X, ZHOU SL, et al.Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity[J]. J Cancer, 2016,7(13): 1907-1914. [39] YANG JD, LIU MC, KISIEL JB.Circulating Tumor DNA and Hepatocellular Carcinoma[J]. Semin Liver Dis, 2019, 39(4): 452-462. [40] LUO Z, MAO X, CUI W.Circular RNA expression and circPTPRM promotes proliferation and migration in hepatocellular carcinoma[J]. Med Oncol, 2019, 36(10): 86. [41] SUN ALLEY, WENG YALI.Research Progress of Circular RNA in Diagnosis and Prognosis of Hepatocellular Carcinoma[J]. World Clinical Drugs, 2020, 41(7): 540-545. [42] LUO Z, MAO X, CUI W.Circular RNA expression and circPTPRM promotes proliferation and migration in hepatocellular carcinoma[J]. Med Oncol, 2019, 36(10): 86. [43] YU J, XU QG, WANG ZG, et al.Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma[J]. J Hepatol, 2018,68(6): 1214-1227. [44] 周剑,孙惠川,王建华,等. 中国原发性肝癌诊治指南(2017版)[J].肝癌,2018,7(3):235-260. [45] SURVEILLANCE GROUP DIAGNOSIS GROUP; STAGING GROUP.Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan[J]. J Formos Med Assoc, 2018,117(5): 381-403. [46] BENSON AB, D'ANGELICA MI, ABBOTT DE, et al. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019[J]. J Natl Compr Canc Netw,2019, 17(4): 302-310. |